Upalakalin, Jan
Upalakalin, Jan was paid $1.14M by Medicaid between Jan 2018 and Dec 2021, across 132 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 25% of everything it billed.
PEORIA, IL 61637
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,373 | $199K | |
| 2019 | 36,975 | $208K | |
| 2020 | 33,390 | $235K | |
| 2021 | 41,133 | $501K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 25% | 5,352 | 4,518 | $291K |
| 80053 | Comprehensive metabolic panel | 6.3% | 13,772 | 11,238 | $73K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 4.9% | 234 | 222 | $56K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.6% | 17,701 | 13,260 | $53K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.5% | 2,243 | 2,146 | $52K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.5% | 2,245 | 2,148 | $51K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.8% | 851 | 784 | $43K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.7% | 3,723 | 3,505 | $30K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.6% | 1,267 | 1,084 | $30K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.1% | 4,569 | 4,223 | $24K |
| 87480 | 2.0% | 1,805 | 1,713 | $23K | |
| 87510 | 2.0% | 1,801 | 1,708 | $23K |
120 more codes
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.7% | 613 | $20K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.7% | 4,676 | $19K |
| 82803 | 1.4% | 1,480 | $16K | |
| 87660 | 1.3% | 1,808 | $15K | |
| 87040 | 1.3% | 1,437 | $14K | |
| 83735 | 1.2% | 3,873 | $14K | |
| 83605 | 1.1% | 2,346 | $13K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.1% | 212 | $12K |
| 87641 | 1.1% | 537 | $12K | |
| 82962 | 1.1% | 6,665 | $12K | |
| 87081 | <1% | 3,223 | $9K | |
| 84484 | <1% | 1,865 | $9K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 709 | $9K |
| 82330 | <1% | 1,031 | $9K | |
| 85730 | <1% | 1,792 | $8K | |
| 87186 | <1% | 1,404 | $8K | |
| 85610 | <1% | 3,519 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 269 | $8K |
| 80061 | Lipid panel | <1% | 2,364 | $8K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,074 | $7K |
| 86780 | <1% | 659 | $6K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 407 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,873 | $6K |
| 83690 | <1% | 1,540 | $5K | |
| 87581 | <1% | 212 | $5K | |
| 81001 | <1% | 3,259 | $5K | |
| 86850 | <1% | 1,680 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 216 | $5K |
| 87486 | <1% | 213 | $5K | |
| 80069 | <1% | 1,119 | $5K | |
| 81025 | <1% | 2,452 | $5K | |
| 84439 | <1% | 1,002 | $4K | |
| 86901 | <1% | 1,783 | $4K | |
| 83880 | <1% | 454 | $4K | |
| 84100 | <1% | 1,775 | $4K | |
| 87088 | <1% | 656 | $4K | |
| 86140 | <1% | 1,484 | $3K | |
| 82607 | <1% | 567 | $3K | |
| 85384 | <1% | 1,076 | $3K | |
| 86900 | <1% | 1,763 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 124 | $3K |
| 82728 | <1% | 776 | $3K | |
| 84466 | <1% | 632 | $3K | |
| 87147 | <1% | 1,514 | $3K | |
| 85379 | <1% | 690 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 332 | $3K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 46 | $3K |
| 87070 | <1% | 818 | $2K | |
| 82570 | <1% | 987 | $2K | |
| 88304 | <1% | 125 | $2K | |
| 86803 | <1% | 258 | $2K | |
| 87340 | <1% | 314 | $2K | |
| 81003 | <1% | 1,896 | $2K | |
| 84702 | <1% | 442 | $2K | |
| 80202 | <1% | 287 | $2K | |
| 87077 | <1% | 437 | $2K | |
| 83615 | <1% | 629 | $2K | |
| 88307 | <1% | 45 | $2K | |
| 85027 | <1% | 621 | $2K | |
| 83540 | <1% | 558 | $2K | |
| 82550 | <1% | 583 | $2K | |
| 85014 | <1% | 1,493 | $2K | |
| 82784 | <1% | 233 | $2K | |
| 86920 | <1% | 326 | $2K | |
| 86038 | <1% | 162 | $1K | |
| 88342 | <1% | 95 | $1K | |
| 85652 | <1% | 892 | $1K | |
| 87493 | <1% | 52 | $1K | |
| 87205 | <1% | 537 | $994.52 | |
| 82746 | <1% | 172 | $973.53 | |
| 85018 | <1% | 901 | $950.16 | |
| 84550 | <1% | 404 | $884.03 | |
| 83970 | <1% | 56 | $855.80 | |
| 80047 | <1% | 199 | $844.56 | |
| 82043 | <1% | 413 | $807.62 | |
| 83516 | <1% | 130 | $743.73 | |
| 84132 | <1% | 503 | $692.42 | |
| 84295 | <1% | 446 | $656.43 | |
| 88341 | <1% | 20 | $613.92 | |
| 82565 | <1% | 277 | $582.82 | |
| 86762 | <1% | 120 | $545.00 | |
| 80076 | <1% | 143 | $516.22 | |
| 84478 | <1% | 238 | $507.50 | |
| 84156 | <1% | 442 | $498.50 | |
| 80074 | <1% | 28 | $496.60 | |
| 83655 | <1% | 84 | $496.36 | |
| 82805 | <1% | 19 | $496.23 | |
| 82248 | <1% | 212 | $433.99 | |
| 84703 | <1% | 105 | $394.87 | |
| 82947 | <1% | 295 | $338.87 | |
| 86480 | <1% | 13 | $309.01 | |
| 87075 | <1% | 46 | $299.23 | |
| 88141 | <1% | 46 | $286.98 | |
| 82247 | <1% | 104 | $249.77 | |
| 87807 | <1% | 39 | $207.20 | |
| 84480 | <1% | 44 | $205.42 | |
| 82785 | <1% | 45 | $188.86 | |
| 85045 | <1% | 140 | $173.28 | |
| 82077 | <1% | 15 | $155.40 | |
| 86003 | <1% | 15 | $148.20 | |
| 86880 | <1% | 44 | $136.30 | |
| 86431 | <1% | 33 | $129.58 | |
| 84481 | <1% | 26 | $125.32 | |
| 82272 | <1% | 109 | $116.00 | |
| 80177 | <1% | 23 | $110.56 | |
| 85049 | <1% | 107 | $108.99 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 12 | $105.60 |
| 82951 | <1% | 14 | $88.20 | |
| 87184 | <1% | 18 | $86.40 | |
| 86706 | <1% | 12 | $84.00 | |
| 85576 | <1% | 13 | $71.40 | |
| 81015 | <1% | 62 | $70.74 | |
| 80164 | <1% | 15 | $66.45 | |
| 85347 | <1% | 34 | $62.88 | |
| 86200 | <1% | 12 | $62.24 | |
| 87015 | <1% | 16 | $61.20 | |
| 87102 | <1% | 13 | $40.30 | |
| 86308 | <1% | 13 | $28.80 | |
| 89050 | <1% | 13 | $22.75 | |
| 84157 | <1% | 14 | $16.10 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.